GLP-1 Medications Primarily Reduce Fat, Not Muscle Mass

A recent analysis of 36 studies indicates that weight loss from GLP-1 receptor agonists primarily involves fat reduction, with only modest lean body mass loss over a 12-month period. After three months, participants experienced a 9% weight reduction, including decreases in visceral adipose tissue and fat body mass, with minimal lean body mass loss.

After 12 months of treatment, significant reductions in visceral adipose tissue and fat body mass were observed. While some lean body mass loss occurred, it was proportionally less than the fat mass reduction.

Prior research, including a study using a mouse model, also suggested that lean mass reduction might be less significant than previously thought, with some loss attributed to non-skeletal muscle tissues. Maintaining muscle mass during GLP-1 treatment is supported by strategies such as adequate protein intake and resistance training.

Continued research on GLP-1s and body composition is considered crucial for understanding long-term health implications, including metabolic rate, physical function, and the risk of sarcopenia, particularly in vulnerable populations.